These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28892201)

  • 1. Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma.
    Pasic I; Wong KM; Lee JJ; Espin-Garcia O; Brhane Y; Cheng D; Chen Z; Patel D; Brown C; Bucur R; Reisman D; Knox JJ; Xu W; Hung RJ; Liu G; Cleary SP
    Mol Carcinog; 2018 Jan; 57(1):106-113. PubMed ID: 28892201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRM polymorphisms, pancreatic cancer risk and survival.
    Segedi M; Anderson LN; Espin-Garcia O; Borgida A; Bianco T; Cheng D; Chen Z; Patel D; Brown MC; Xu W; Reisman D; Gallinger S; Cotterchio M; Hung R; Liu G; Cleary SP
    Int J Cancer; 2016 Dec; 139(11):2474-81. PubMed ID: 27487558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome.
    Korpanty GJ; Eng L; Qiu X; Faluyi OO; Renouf DJ; Cheng D; Patel D; Chen Z; Tse BC; Knox JJ; Dodbiba L; Teichman J; Azad AK; Wong R; Darling G; Reisman D; Cuffe S; Liu G; Xu W
    Oncotarget; 2017 Apr; 8(17):28093-28100. PubMed ID: 28427211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.
    Liu G; Cuffe S; Liang S; Azad AK; Cheng L; Brhane Y; Qiu X; Cescon DW; Bruce J; Chen Z; Cheng D; Patel D; Tse BC; Laurie SA; Goss G; Leighl NB; Hung R; Bradbury PA; Seymour L; Shepherd FA; Tsao MS; Chen BE; Xu W; Reisman DN
    Clin Cancer Res; 2017 May; 23(10):2460-2470. PubMed ID: 27827316
    [No Abstract]   [Full Text] [Related]  

  • 5. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma.
    Endo M; Yasui K; Zen Y; Gen Y; Zen K; Tsuji K; Dohi O; Mitsuyoshi H; Tanaka S; Taniwaki M; Nakanuma Y; Arii S; Yoshikawa T
    Liver Int; 2013 Jan; 33(1):105-17. PubMed ID: 23088494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insertion/deletion polymorphisms in the promoter region of BRM contribute to risk of hepatocellular carcinoma in Chinese populations.
    Gao X; Huang M; Liu L; He Y; Yu Q; Zhao H; Zhou C; Zhang J; Zhu Z; Wan J; Jiang X; Gao Y
    PLoS One; 2013; 8(1):e55169. PubMed ID: 23359823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
    Lee MJ; Kuehne N; Hueniken K; Liang S; Rai S; Sorotsky H; Herman M; Shepshelovich D; Bruce J; Liang M; Patel D; Cheng D; Chen Z; Eng L; Brown MC; Cho J; Leighl NB; de Perrot M; Reisman D; Xu W; Bradbury PA; Liu G
    Mol Carcinog; 2019 Nov; 58(11):1960-1973. PubMed ID: 31355511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.
    Wong KM; Qiu X; Cheng D; Azad AK; Habbous S; Palepu P; Mirshams M; Patel D; Chen Z; Roberts H; Knox J; Marquez S; Wong R; Darling G; Waldron J; Goldstein D; Leighl N; Shepherd FA; Tsao M; Der S; Reisman D; Liu G
    Cancer Med; 2014 Apr; 3(2):426-33. PubMed ID: 24519853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two functional indel polymorphisms in the promoter region of the Brahma gene (BRM) and disease risk and progression-free survival in colorectal cancer.
    Yu Y; Cheng D; Parfrey P; Liu G; Savas S
    PLoS One; 2018; 13(6):e0198873. PubMed ID: 29894502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk.
    Wang JR; Gramling SJ; Goldstein DP; Cheng D; Chen D; Azad AK; Tse A; Hon H; Chen Z; Mirshams M; Simpson C; Huang SH; Marquez S; O'Sullivan B; Liu FF; Roberts H; Xu W; Brown DH; Gilbert RW; Gullane PJ; Irish JC; Reisman DN; Liu G
    Carcinogenesis; 2013 May; 34(5):1012-7. PubMed ID: 23322154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between IL6 -572G/C polymorphism and hepatocellular carcinoma in men].
    Liu S; Qiu XQ; Zeng XY; Bai H; Bei CH; Yang Y
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jun; 20(6):463-7. PubMed ID: 23044206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma.
    Xie K; Liu J; Zhu L; Liu Y; Pan Y; Wen J; Ma H; Zhai X; Hu Z
    Cancer Epidemiol; 2013 Dec; 37(6):998-1002. PubMed ID: 24103425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genetic variant in the promoter of CD46 is associated with the risk and prognosis of hepatocellular carcinoma.
    Liu F; Luo L; Liu Z; Wu S; Zhang W; Li Q; Peng Y; Wei Y; Li B
    Mol Carcinog; 2020 Nov; 59(11):1243-1255. PubMed ID: 32869896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cytokine gene polymorphisms on prognosis in hepatocellular carcinoma after radical surgery resection.
    Pan D; Zeng X; Yu H; Yang Y; Bei C; Bai H; Qiu X
    Gene; 2014 Jul; 544(1):32-40. PubMed ID: 24768182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma.
    Chien MH; Yeh KT; Li YC; Hsieh YH; Lin CH; Weng MS; Kuo WH; Yang SF
    J Surg Oncol; 2011 Sep; 104(3):299-304. PubMed ID: 21462191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
    Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
    Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genetic variant in primary miR-378 is associated with risk and prognosis of hepatocellular carcinoma in a Chinese population.
    An J; Liu J; Liu L; Liu Y; Pan Y; Huang M; Qi F; Wen J; Xie K; Ma H; Shen H; Hu Z
    PLoS One; 2014; 9(4):e93707. PubMed ID: 24751683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variants in de novo lipogenic pathway genes predict the prognosis of surgically-treated hepatocellular carcinoma.
    Jiang H; Dai J; Huang X; Chen Y; Qu P; Li J; Yi C; Yang Y; Zhang K; Huang Q
    Sci Rep; 2015 Mar; 5():9536. PubMed ID: 25826294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase gene polymorphisms as important contributors affecting hepatocellular carcinoma prognosis.
    Wang X; Sun X; Du X; Zhou F; Yang F; Xing J; Dong G; Guo X
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):319-326. PubMed ID: 28043790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A functional polymorphism in PER3 gene is associated with prognosis in hepatocellular carcinoma.
    Zhao B; Lu J; Yin J; Liu H; Guo X; Yang Y; Ge N; Zhu Y; Zhang H; Xing J
    Liver Int; 2012 Oct; 32(9):1451-9. PubMed ID: 22809120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.